Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lung Cancer Heterogeneity and New Strategies for Drug Therapy.

Annual review of pharmacology and toxicology - 6 Jan 2018

Wang Diane C, Wang William, Zhu Bijun, Wang Xiangdong

Abstract excerpt

Lung cancer heterogeneity plays an important role in the development of drug resistance. Comprehensive molecular characterizations of lung cancer can describe hereditary and somatic gene changes, mutation, and heterogeneity. We discuss heterogeneity specificity, characterization, and roles of PIK3CD, TP53, and KRAS, as well as target-driven therapies and strategies applied in clinical trials based on a proposed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy

Share to Genetic Heterogeneity

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 28977762
DOI: 10.1146/annurev-pharmtox-010716-104523

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lung Cancer Heterogeneity and New Strategies for Drug Therapy.PMID 28977762Read ↗

The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapiesSemantic proximity Read ↗

Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistanceSemantic proximity Read ↗

Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.Semantic proximity Read ↗

Heterogeneity in Lung Cancer.Semantic proximity Read ↗

Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer.Semantic proximity Read ↗

Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?Semantic proximity Read ↗

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapySemantic proximity Read ↗

[Advances of heterogeneity of EGFR in non-small cell lung cancer].Semantic proximity Read ↗

Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.Semantic proximity Read ↗

Lung tumoroids as a testing platform for precision CAR T-cell therapySemantic proximity Read ↗

A novel artificial lung organoid for simulating a patient derived adenocarcinoma of lung for personalized oncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.